Results 81 to 90 of about 2,594,817 (409)

Heteromerization Modulates mu Opioid Receptor Functional Properties in vivo

Frontiers in Pharmacology, 2018
Mu opioid receptors modulate a large number of physiological functions. They are in particular involved in the control of pain perception and reward properties.
Muzeyyen Ugur, Lyes Derouiche, Dominique Massotte   +2 more
doaj   +1 more source

GRKs as Key Modulators of Opioid Receptor Function

Cells, 2020
Understanding the link between agonist-induced phosphorylation of the mu-opioid receptor (MOR) and the associated physiological effects is critical for the development of novel analgesic drugs and is particularly important for understanding the ...
Laura Lemel, J Robert Lane, Meritxell Canals   +2 more
doaj   +1 more source

Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice. [PDF]

PLoS ONE, 2014
Neuropeptide FF (NPFF) is known to be an endogenous opioid-modulating peptide. Nevertheless, very few researches focused on the interaction between NPFF and endogenous opioid peptides. In the present study, we have investigated the effects of NPFF system
Zi-long Wang, Quan Fang, Zheng-lan Han, Jia-xin Pan, Xu-hui Li, Ning Li, Hong-hai Tang, Pei Wang, Ting Zheng, Xue-mei Chang, Rui Wang   +10 more
doaj   +1 more source

Solid Tumor Opioid Receptor Expression and Oncologic Outcomes: Analysis of the Cancer Genome Atlas and Genotype Tissue Expression Project

Frontiers in Oncology, 2022
BackgroundOpioid receptors are expressed not only by neural cells in the central nervous system, but also by many solid tumor cancer cells. Whether perioperative opioids given for analgesia after tumor resection surgery might inadvertently activate tumor
Amparo Belltall, Amparo Belltall, Sheila Zúñiga-Trejos, Iris Garrido-Cano, Iris Garrido-Cano, Pilar Eroles, Pilar Eroles, Maria Pilar Argente-Navarro, Maria Pilar Argente-Navarro, Donal J. Buggy, Donal J. Buggy, Oscar Díaz-Cambronero, Oscar Díaz-Cambronero, Oscar Díaz-Cambronero, Guido Mazzinari, Guido Mazzinari, Guido Mazzinari   +16 more
doaj   +1 more source

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice. [PDF]

, 2015
RATIONALE Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice.
C Giuliano, C Giuliano, David N. Stephens, David R. Wille, DM Ignar, DN Stephens, DW Oslin, EA Rabiner, Edward T. Bullmore, EE Codd, F Kiefer, GH Jones, H Wit de, H Ziauddeen, HM Pettinati, JR Volpicelli, JS Rhodes, Kay Maltby, LA Berner, LA Parker, LD Middaugh, LS Hwa, Manolo Mugnaini, NK Kamdar, P Monti, PJ Nathan, PJ Nathan, Pradeep Nathan, S Loeber, Sam R. Miller, Sandra Sanchez-Roige, Tamzin L. Ripley, TJ Phillips, TL Ripley   +33 more
core   +1 more source

Impact of Positive Lifestyle Behaviors on Direct Health Care Cost Savings for Low Back Pain

Arthritis Care &Research, EarlyView.
Objective This study aimed to investigate the relationship between a previously purpose‐developed lifestyle behavior scale and health care cost savings related to low back pain (LBP). Methods This longitudinal study used data from the Australian Twin Back (AUTBACK) study. LBP and lifestyle behavior measures were collected at baseline. Physical activity
Ye Tian, Katharine E. Roberts, Michelle Hall, Paula R. Beckenkamp, Angelo Sabag, Karoline Moe, Ana Paula Carvalho‐e‐Silva, Emily J. Callander, Paulo H. Ferreira   +8 more
wiley   +1 more source

Methadone for Cancer Pain

Palliative Care, 2010
Pain is one of the most common and incapacitating symptoms experienced by patients with advanced cancer. Methadone is a potent opioid with strong affinity for the µ opioid receptor. In addition to being a potent µ opioid receptor ligand, methadone blocks
Eric E. Prommer
doaj   +2 more sources

Ethanol reversal of tolerance to the respiratory depressant effects of morphine [PDF]

, 2015
Opioids are the most common drugs associated with unintentional drug overdose. Death results from respiratory depression. Prolonged use of opioids results in the development of tolerance but the degree of tolerance is thought to vary between different ...
A Fugelstad, A Fugelstad, Abi Lyndon, AJ Ruttenber, Anne Lingford-Hughes, AR Lingford-Hughes, B Levine, BM Mathers, CA Paronis, Chris Bailey, CK Kuo, CN Lessov, CP Bailey, CP Bailey, CP Bailey, E Kelly, E Valjent, Eamonn Kelly, EB Rex, EJ Waite, F Chen, FL Smith, FL Smith, Graeme Henderson, GS Ling, H Sakakibara, HW Matthes, HY Lin, I Rodriguez-Martin, J Llorente, J McPherson, J Reneau, JM White, Joanne Roberts, John MacLachlan, JT Williams, JW Lewis, KL McGilliard, L He, LC Hull, LC Saland, LJ Sim-Selley, LM Bohn, LQ Hong-Brown, M Aliczki, M Hickman, M Hickman, M Inoue, M Pierce, Matthew Hickman, N Quillinan, NG Shah, R Cornish, R Romberg, Rob Hill, S Darke, S Darke, S Kishioka, Sarah Withey, SJ Slater, SV Dighe, TC Green, Yvonne Kershaw   +62 more
core   +3 more sources

Structural basis for bifunctional peptide recognition at human δ-Opioid receptor

Nature Structural &Molecular Biology, 2015
Bifunctional μ- and δ-opioid receptor (OR) ligands are potential therapeutic alternatives, with diminished side effects, to alkaloid opiate analgesics.
G. Fenalti, N. Zatsepin, Cecilia Betti, P. Giguère, G. Han, A. Ishchenko, Wei Liu, Karel Guillemyn, Haitao Zhang, Daniel James, Dingjie Wang, U. Weierstall, J. Spence, S. Boutet, M. Messerschmidt, Garth J. Williams, C. Gati, O. Yefanov, T. White, D. Oberthuer, M. Metz, C. Yoon, A. Barty, H. Chapman, S. Basu, J. Coe, C. Conrad, R. Fromme, P. Fromme, D. Tourwé, P. Schiller, B. Roth, S. Ballet, V. Katritch, R. Stevens, V. Cherezov   +35 more
semanticscholar   +1 more source

Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States

Arthritis Care &Research, EarlyView.
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech, Charles G. Frech, W. David Merryman, Andrew Sternlicht, Justin Baba   +4 more
wiley   +1 more source